Rituximab for Multiple Sclerosis
Yes, rituximab is an appropriate and effective disease-modifying therapy option for a 37-year-old woman with MRI-confirmed multiple sclerosis, particularly if she has active relapsing disease.
Evidence Supporting Rituximab Use
Rituximab has emerged as a highly effective off-label treatment for MS, despite lacking FDA approval for this indication. The FDA label 11 does not include MS as an approved indication—rituximab is approved for conditions like non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, GPA, MPA, and pemphigus vulgaris. However, extensive real-world evidence and clinical trials support its use in MS.
Efficacy in Relapsing MS
For first-line treatment in active relapsing MS:
- Rituximab likely delays relapse compared to interferon beta or glatiramer acetate (HR 0.14,95% CI 0.05 to 0.39) 2
- May delay relapse compared to dimethyl fumarate (HR 0.29) and natalizumab (HR 0.24) 2
- One RCT showed rituximab may reduce relapse recurrence (OR 0.16,95% CI 0.04 to 0.57) compared to dimethyl fumarate 2
For switching therapy in relapsing MS:
- Rituximab likely delays relapse versus interferon beta/glatiramer acetate (HR 0.18,95% CI 0.07 to 0.49) 2
- Likely delays relapse versus fingolimod (HR 0.08,95% CI 0.02 to 0.32) 2
- Results in little to no difference compared with natalizumab (HR 0.96) 2
Real-World Outcomes
Multiple observational studies demonstrate strong clinical effectiveness:
- 87% of patients experienced no relapses after rituximab initiation 3
- Annualized relapse rate dropped from 1.24 to 0.16 in relapsing-remitting MS patients 3
- Meta-analysis showed significant decrease in EDSS scores (SMD: -0.44,95% CI -0.85, -0.03) 4
Safety Profile
Common Adverse Events
The safety profile is generally acceptable but requires monitoring:
Infections are the primary concern:
- Rituximab likely increases serious common infections compared to interferon beta/glatiramer acetate (OR 1.71,95% CI 1.11 to 2.62) and natalizumab (OR 1.58,95% CI 1.08 to 2.32) 2
- Pooled prevalence of infections: 24% (95% CI 13%, 36%) 4
- However, absolute risk remains low in real-world practice 3
Other adverse events:
- Infusion-related reactions: 28.63% pooled prevalence 4, occurring in 6% in one cohort 3
- Urinary tract infections: 8.4% 3
- Malignancy risk: 0.39% pooled prevalence 4
- Mortality: Very few events across studies 2
Important Safety Consideration
Extended interval dosing (≥6 months + ≥4 weeks) may reduce serious infection risk without compromising disease control 5, showing significantly lower incidence of serious infectious adverse events at both 6 months (P=0.03) and 12 months (P=0.04) compared to standard dosing.
Clinical Context and Guidelines
The 2025 ECTRIMS/EBMT guidelines 6 discuss autologous HSCT for MS and list rituximab among acceptable prior DMTs in ongoing trials (RAM-MS, BEAT-MS, STAR-MS, NET-MS), indicating its recognition as a legitimate treatment option within the MS community. These trials compare HSCT to high-efficacy DMTs including rituximab, alemtuzumab, cladribine, natalizumab, and ocrelizumab.
The MS International Federation developed evidence-based recommendations 7 specifically supporting rituximab use in low-resource settings, with seven conditional recommendations favoring its use for relapsing MS and active progressive MS compared to no treatment and several on-label DMTs.
Practical Recommendations
For your 37-year-old patient with MRI-confirmed MS:
If she has active relapsing disease: Rituximab is an excellent option as either first-line or switching therapy 829
Dosing considerations: While optimal dosing remains debated 9, extended interval dosing (every 6-9 months) appears safer regarding infections without compromising efficacy 5
Pre-treatment screening: Although not MS-specific in the FDA label, standard monitoring for infections, liver function, and cardiac assessment should be performed 1
Key advantage: Rituximab is significantly less expensive than approved anti-CD20 therapies (ocrelizumab, ofatumumab) while demonstrating comparable efficacy 87
Critical Caveat
The primary barrier is regulatory, not clinical: Rituximab remains off-label for MS despite robust evidence 87. This may affect insurance coverage and reimbursement depending on your healthcare system. However, the evidence strongly supports its clinical use, particularly when access to approved high-efficacy DMTs is limited or cost is prohibitive.
The evidence on disability progression is less certain than for relapse prevention 2, but this reflects limitations in study design rather than lack of effect. The 2025 Cochrane review 2 notes that rituximab compares favorably with approved DMTs for preventing relapses in relapsing MS.